Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume - Here's Why

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) saw an uptick in trading volume on Tuesday . 2,502,857 shares traded hands during trading, an increase of 65% from the previous session's volume of 1,513,499 shares.The stock last traded at $20.74 and had previously closed at $20.68.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. HC Wainwright restated a "buy" rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Wall Street Zen downgraded shares of Genmab A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Finally, Truist Financial lowered their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Price Performance

The company has a market cap of $13.34 billion, a P/E ratio of 11.82, a PEG ratio of 6.98 and a beta of 0.96. The business's 50 day moving average price is $20.92 and its 200-day moving average price is $20.73.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The company had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. As a group, research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of large investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC lifted its position in Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares during the period. Headlands Technologies LLC raised its stake in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after buying an additional 1,464 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after buying an additional 1,070 shares during the period. Lindbrook Capital LLC boosted its stake in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after acquiring an additional 950 shares during the last quarter. Finally, Barclays PLC boosted its stake in Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after acquiring an additional 2,285 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.